Manufacturer's reference range: Adult male 22 - 322 ng/mL Adult female 13 - 150 ng/mL See also: Am J Clin Path, 70: 79, 1978; Can Med Assoc J, 114: 417, 1976 Iron deficiency 0-20 ng/mL

New analytical immunoassay instituted 4/24/00 at 1000. Please print, complete and submit the Advance Beneficiary Notice (ABN) along with the Laboratory Requisition before shipping the specimen.

The assay is unaffected by icterus (bilirubin is less than 65 mg/dL), hemolysis (Hb is less than 500 mg/dL), lipemia (Intralipid is less than 3300 mg/dL) and biotin is less than 50 ng/ml. (criterion: recovery within plus or minus 10% of initial value). In patients receiving therapy with high biotin doses (i.e. is greater than 5 mg/day) no sample should be taken until at least 8 hours after the last biotin administration. No interference was observed from rheumatoid factors up to a concentration of 2500 U/mL. No high dose hook effect at ferritin concentrations of up to 100 000 ng/mL. In vitro tests were performed on 19 commonly used pharmaceuticals. No interference with the assay was found. Iron2+- and iron3+-ions at therapuetic concentrations do not interfere in the Ferritin assay. As with all tests containing monoclonal antibodies, erroneous findings may be obtained from samples taken from patients who have been treated with monoclonal mouse antibodies or who have received them for diagnostic purposes. Ferritin contains additives which minimize these effects. In rare cases interference due to extremely high titers of antibodies to streptavidin and ruthenium can occur. For diagnostic purposes, the Ferritin findings should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.